The US market for Hemostats and Sealants accelerated substantially in Q318 vs Q218
As reported in SmartTRAK’s Financial Dashboard, every manufacturer in the Hemostats and Sealants market, with the exception of Pfizer, saw revenue growth in Q318. Leading the way were Baxter, with its integration of the Mallinckrodt portfolio, as well as Ethicon and Integra, while Pfizer posted...
Among the many topics covered in the Q318 US Hemostats and Sealants Market Recap are:
- Ethicon Continues to Lead Hemostats and Sealants
- Hemostats Are Strong Across Board
- Fibrin Leads The Way In Sealants
- Other Important Q318 events
The US Hemostats and Sealants market increased by +7.9% YoY in Q318, up from +3.8% in Q218. Growth was driven by...
Read the entire Q318 US Hemostats and Sealants Market Recap including news, data and analysis*...
*This article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
